MXPA05011769A - Estructura cristalina. - Google Patents

Estructura cristalina.

Info

Publication number
MXPA05011769A
MXPA05011769A MXPA05011769A MXPA05011769A MXPA05011769A MX PA05011769 A MXPA05011769 A MX PA05011769A MX PA05011769 A MXPA05011769 A MX PA05011769A MX PA05011769 A MXPA05011769 A MX PA05011769A MX PA05011769 A MXPA05011769 A MX PA05011769A
Authority
MX
Mexico
Prior art keywords
pde5
crystal
ligands
drug design
crystals
Prior art date
Application number
MXPA05011769A
Other languages
English (en)
Inventor
Wendy Elaine Taylor
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA05011769A publication Critical patent/MXPA05011769A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invencion se refiere a los cristales humedecibles de una fosfodiesterasa 5 (abreviadamente en ingles PDE5) y sus usos en la identificacion de ligandos de la PDE5, incluyendo los ligandos de la PDE5 y los compuestos inhibidores. La presente invencion tambien se refiere a los procedimientos de identificacion de tales compuestos inhibidores de la PDE5 y su uso medico. La presente invencion se refiere adicionalmente a los cristales de la PDE5 en los que los ligandos se pueden humedecer y los cristales de la PDE5 comprendiendo los ligandos de la PDE5 que se han humedecido en el cristal.
MXPA05011769A 2003-05-01 2004-04-21 Estructura cristalina. MXPA05011769A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0310058 2003-05-01
PCT/IB2004/001332 WO2004097010A1 (en) 2003-05-01 2004-04-21 Crystal of pde5, its crystal structure and its use in drug design

Publications (1)

Publication Number Publication Date
MXPA05011769A true MXPA05011769A (es) 2006-01-26

Family

ID=33397043

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011769A MXPA05011769A (es) 2003-05-01 2004-04-21 Estructura cristalina.

Country Status (10)

Country Link
EP (1) EP1623026A1 (es)
JP (1) JP2006525801A (es)
AR (1) AR044133A1 (es)
BR (1) BRPI0409931A (es)
CA (1) CA2522472A1 (es)
CL (1) CL2004000926A1 (es)
MX (1) MXPA05011769A (es)
RU (1) RU2005133628A (es)
TW (1) TW200510540A (es)
WO (1) WO2004097010A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100152278A1 (en) * 2007-05-02 2010-06-17 Merck & Co., Inc RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1038963T3 (da) * 1993-05-27 2009-11-23 Univ Washington Cyklisk GMP-binding, cyklisk GMP-specifikke phosphodiesterasematerialer og fremgangsmåder
GB9923968D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Therapeutic agents
GB0126417D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Crystal structure

Also Published As

Publication number Publication date
BRPI0409931A (pt) 2006-04-25
WO2004097010A1 (en) 2004-11-11
TW200510540A (en) 2005-03-16
JP2006525801A (ja) 2006-11-16
AR044133A1 (es) 2005-08-24
EP1623026A1 (en) 2006-02-08
CA2522472A1 (en) 2004-11-11
RU2005133628A (ru) 2007-05-10
CL2004000926A1 (es) 2005-04-22

Similar Documents

Publication Publication Date Title
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
WO2004004658A3 (en) Methods and compositions relating to isoleucine boroproline compounds
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
DE60210093D1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und -tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
AP2004003161A0 (en) Substituted benzazoles and use thereof as raf kinase inhibitors.
EP1592689A4 (en) 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE FOR THE TREATMENT OR PREVENTION OF DIABETES
EP1589969A4 (en) 3-AMINO-4-PHENYLBUTANEAN DERIVATEALS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
EP1651623A4 (en) HEXAHYDRODIAZEPINONES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OR PREVENTION OF DIABETES
AU2003213606A8 (en) Mp53s as modifiers of the p53 pathway and methods of use
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
EP1495130A4 (en) USE OF BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS
MX2010006378A (es) Moduladores de gamma secretasa.
MY142252A (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods
UA83041C2 (ru) Композиция, которая включает ингибитор pde4 и ингибитор pde5
WO2007120333A3 (en) Tetracyclic kinase inhibitors
AU2003279442A8 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
ZA200501128B (en) Biphasic composition induced by polydextrose
WO2006023704A3 (en) Lonidamine analogues and their use in male contraception and cancer treatment
MXPA05009014A (es) Antagonistas del receptor ccr-3.
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors
SI1781296T1 (sl) Kinazolinski derivati in njihova uporaba pri zdravljenju trombocitemije
HK1077059A1 (en) Salt of (s)-pantoprazole and its hydrates (s)-
MXPA04001419A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson.
YU36104A (sh) Kristalna struktura fosfodiesteraza 5 i njihova upotreba